WIM
ACXP icon

Westside Investment Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Westside Investment Management’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.12K Buy
+1,650
New +$4.68K ﹤0.01% 1219

Other funds holding ACXP

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return

Westside Investment Management's ACXP Position: Q1 2026 in Review

Westside Investment Management opened a new position in Acurx Pharmaceuticals (ACXP) in Q1 2026: 1,650 shares worth $6.12K. The stake represents ﹤0.01% of the portfolio and ranks #1219 among its holdings.

21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

  • Westside Investment Management held 1,650 shares of Acurx Pharmaceuticals worth $6.12K as of Q1 2026.
  • Acurx Pharmaceuticals was a new Westside Investment Management position in Q1 2026.
  • Acurx Pharmaceuticals made up ﹤0.01% of Westside Investment Management's portfolio in Q1 2026, its #1219 holding.
  • 21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Westside Investment Management's 13F filing for Q1 2026, filed 4 May 2026.